CD3 News and Research

RSS

Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published in the PNAS journal

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.

9 Sep 2023

A SARS-CoV-2 spike-targeting bispecific T-cell engager strategy for controlling SARS-CoV-2 infection

Researchers described a novel strategy for controlling severe acute respiratory syndrome coronavirus 2.

5 Jun 2023

Unlocking the potential of RNA lipid nanoparticles to revolutionize cancer treatment

This paper discusses the use of RNA lipid nanoparticles for cancer immunotherapy, which has shown promising results in clinical use. However, only a small percentage of patients respond to existing immunotherapies, and the paper explores opportunities for improvement.

18 Apr 2023

Avanced genome editing technology could be used as a one-time treatment for CD3 delta SCID

A new UCLA-led study suggests that advanced genome editing technology could be used as a one-time treatment for the rare and deadly genetic disease CD3 delta severe combined immunodeficiency.

21 Mar 2023

Detecting tissue-resident memory T cells in solid tumors

In this interview, NewsMedical talks with Cerba Research about in situ multiplex analysis of regulatory and effector T cells in tumors.

16 Mar 2023

Immunochemistry multiplex for solid tumor analytical validation

In this interview, NewsMedical exchanges with Cerba on how to use T-regulatory immunochemsitry multiplex for solid tumor analytical validation.

From Cerba Research 16 Mar 2023

Analyzing regulatory and effector T cells in tumors

In this interview, Cerba Research describes how its teams were able to detect resident memory T cells in solid tumors thanks to multiplex immunofluorescence.

From Cerba Research 16 Mar 2023

Achieving immune cell checkpoint profiling

NewsMedical exchanges with Cerba Research on how to achieve immune cell checkpoint profiling of solid tumors by multiplex immunofluorescence.

From Cerba Research 16 Mar 2023

Nasal administration of a fully human anti-CD3 monoclonal antibody modulates T cell inflammatory responses in COVID-19

Researchers assessed the impact of an anti-CD3 monoclonal antibody called Foralumab in COVID-19 treatment.

9 Mar 2023

Pilot trial tests nasal monoclonal antibody treatment for COVID-19

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody.

8 Mar 2023

Study identifies the essential genetic and immunologic perturbations occurring in patients with long COVID lung fibrosis

Researchers elucidated immunologic and genetic perturbations in long COVID patients with pulmonary fibrosis.

3 Mar 2023

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

New adoptive T cell therapies -; in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, and then infused back into the same patient -; are changing the prospects of cancer patients.

10 Feb 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

Scientists find key reason for ongoing loss of smell in long-COVID

In a recent study published in the journal Science Translational Medicine, researchers reported that long-term anosmia following coronavirus disease 2019 (COVID-19) could be a result of persistent T-cell mediated inflammation occurring in the olfactory epithelium even after the elimination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the olfactory tissue.

27 Dec 2022

Protein expression signature distinguishes early from late stage diffuse alveolar damage

Researchers identified a protein expression signature that can distinguish early diffuse alveolar damage (DAD) from late DAD in coronavirus disease 2019 (COVID-19) patients.

15 Dec 2022

Study suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patients

Researchers assessed the association of enhanced migratory or activated CD8+ T cell and reduced avidity reactive cellular response due to post-acute COVID-19 syndrome (PASC).

13 Dec 2022

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

From Cerba Research 6 Dec 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

How does COVID-19 and its treatment affect testicular function?

Researchers summarized available information related to the reproductive effects of COVID-19 in men.

23 Oct 2022

CD3 News and Research

Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published in the PNAS journal

A SARS-CoV-2 spike-targeting bispecific T-cell engager strategy for controlling SARS-CoV-2 infection

Unlocking the potential of RNA lipid nanoparticles to revolutionize cancer treatment

Avanced genome editing technology could be used as a one-time treatment for CD3 delta SCID

Detecting tissue-resident memory T cells in solid tumors

Immunochemistry multiplex for solid tumor analytical validation

Analyzing regulatory and effector T cells in tumors

Achieving immune cell checkpoint profiling

Nasal administration of a fully human anti-CD3 monoclonal antibody modulates T cell inflammatory responses in COVID-19

Pilot trial tests nasal monoclonal antibody treatment for COVID-19

Study identifies the essential genetic and immunologic perturbations occurring in patients with long COVID lung fibrosis

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Scientists find key reason for ongoing loss of smell in long-COVID

Protein expression signature distinguishes early from late stage diffuse alveolar damage

Study suggests persistent inflammatory response triggered by SARS-CoV-2 may be responsible for observed sequelae in PASC patients

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

The critical role of flow cytometry in CAR+ T-Cell trials

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

How does COVID-19 and its treatment affect testicular function?

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News